source
- Altimmune to discuss Phase 3 design for alcohol use disorder drug with FDAAltimmune is preparing to meet the FDA in December to discuss the design of a pivotal Phase 3 trial for its glucagon/GLP-1 dual receptor agonist pemvidutide. The Phase 2 RECLAIM study enrolled abo…
- Delix Therapeutics secures $100 million Series C to advance psychedelic pipelineDelix Therapeutics announced it has closed a $100 million Series C financing round. The capital will be used to accelerate development of its pipeline of psychedelic and neuroplastogen candidates…